Corcept Therapeutics | CORT - Operating Profit


Corcept Therapeutics reported $-49.6M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Alaunos Therapeutics USD -1.01M 175K Mar/2026
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Ardelyx USD -32.79M 37.89M Mar/2026
Aurora Cannabis CAD -10.03M 25.76M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -27.47M 14.81M Mar/2026
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
J&J USD 7.48B 860M Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 4.62M 1.43M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
TG Therapeutics USD 34.8M 15.7M Mar/2026